

Title:

Early SARS-CoV-2 reinfections within 60 days highlight the need to consider antigenic variations together with duration of immunity in defining retesting policies

Authors:

Louis Nevejan¹, Lize Cuypers¹, Lies Laenen¹, Liselotte Van Loo², François Vermeulen², Elke Wollants³, Ignace Van Hecke¹, Stefanie Desmet^{1,4}, Katrien Lagrou^{1,4}, Piet Maes³, Emmanuel André^{1,4}

Affiliations:

¹ Department of Laboratory Medicine, National Reference Center for Respiratory Pathogens, UZ Leuven – University Hospitals Leuven, Leuven, Belgium

² Department of Pediatrics, UZ Leuven – University Hospitals Leuven, Leuven, Belgium

³ KU Leuven, Rega Institute, Department of Microbiology, Immunology and Transplantation, Laboratory of Clinical and Epidemiological Virology, Leuven, Belgium

⁴ KU Leuven Department of Microbiology, Immunology and Transplantation, Laboratory of Clinical Microbiology, Leuven, Belgium

Corresponding author:

Louis Nevejan

Department of Laboratory Medicine, National Reference Center for Respiratory Pathogens

UZ Leuven – University Hospitals Leuven

Herestraat 49

3000 Leuven – BELGIUM

louis.nevejan@uzleuven.be

Conflicts of interest: LN, LC, LL, LVL, FV, EW, IVH, SD, KL, PM, EA: none to declare

Funding source: none to declare

Acknowledgment: UZ Leuven, as national reference center for respiratory pathogens, is supported by Sciensano, which is gratefully acknowledged

1 **Abstract:**

2 The emergence of the SARS-CoV-2 Omicron variant, characterized by a significant antigenic diversity
3 compared to the previous Delta variant, had led to a decrease in antibody efficacy in both
4 convalescent and vaccinees' sera resulting in high number of reinfections and breakthrough cases
5 worldwide. However, to date, reinfections are defined by the ECDC as two positive tests ≥ 60 days
6 apart, influencing retesting policies after an initial positive test in several European countries. We
7 illustrate by a clinical case supplemental by epidemiological data that early reinfections do occur
8 within 60 days especially in young, unvaccinated individuals. In older patient groups, unvaccinated
9 and patients with a basic vaccination scheme are more vulnerable to reinfections compared to
10 patients who received a first booster vaccine. For this reason, we consider that the duration of
11 protection offered by a previous infection should be reconsidered, in particular when a shift between
12 consecutive SARS-CoV-2 variants occurs.

13 **Text:**

14 The sequential emergence of SARS-CoV-2 variants of concern (VOCs), characterized by both an
15 antigenic drift and higher transmissibility, has been observed in all countries around the world at
16 least three times during the last 13 months (1). These abrupt viral population replacements
17 inevitably impact the residual population immunity, independently from the timing of a previous
18 infection. While the SARS-CoV-2 Delta variant showed a limited antigenic diversity with previous
19 VOCs, Omicron differs more significantly from other VOCs than any previous variant did at the time
20 they emerged (2). The resulting decrease of antibody efficacy in both convalescent and vaccinees'
21 sera drives the high number of reinfection and breakthrough cases observed with Omicron compared
22 to the observations made during the previous waves (3–6).

23 To date, reinfections with SARS-CoV-2 are defined by the European Centre for Disease Prevention
24 and Control (ECDC) as two positive tests ≥ 60 days apart (technical report April 8, 2021) (7). This
25 definition has influenced testing strategies in several countries, and many countries therefore do not
26 recommend retesting patients for six months after a positive test. We consider that this definition
27 needs to be revised.

28 To illustrate our point, we report here a case of an immunocompetent boy with no significant
29 medical history, who was infected with SARS-CoV-2 Delta variant (≥ 7.0 log copies/mL, sublineage
30 AY.43) in early December, 2021, concomitant with an outbreak at the patient's school (Table 1). The
31 patient's sibling and one parent were infected as well (≥ 7.0 log copies/mL respectively ≥ 5.0 - < 7.0 log
32 copies/mL). All three developed mild COVID-19 symptoms. The other parent, boosted 1 month
33 before, tested negative twice. Due to an unrelated trauma two weeks later, the patient was admitted

34 to the hospital for surgery. Systematic SARS-CoV-2 screening performed at admission detected a low
35 viral load (<3.0 log copies/mL), interpreted as viral remnant of the past infection 16 days earlier and
36 typing of this sample was not possible due to low viral load. Three weeks later, the patient was
37 readmitted for a second stage surgery. Preprocedural SARS-CoV-2 screening detected a strong
38 positive result (5.1 log copies/mL) with Omicron BA.1 variant, therefore only 39 days after the
39 patient's infection with Delta. The patient remained pauci-symptomatic. High-risk contact screening
40 of the patient's brother detected a low viral load (<3.0 log copies/mL, untypable due to the low viral
41 load), the mother tested SARS-CoV-2 negative and the father was not retested.

42 Further, to put this clinical case into a wider epidemiological context, we estimated the incidence of
43 early reinfections with 1) Omicron BA.1 after Delta infection and 2) with Omicron BA.2 after BA.1
44 infections in a community setting (Flemish Brabant, Belgium).

45 Between December 1, 2021 and February 7, 2022 (n = 9 weeks), a period characterized by the viral
46 replacement of Delta by Omicron BA.1, a total of 56,831 ambulatory patients tested SARS-CoV-2
47 positive at the federal testing platform located in Leuven, Belgium. Among these, 0.16% (91 out of
48 56,831) had the S-gene detected in a first sample using the TaqPath PCR test (suggestive of Delta
49 infection), while S-gene target failure (SGTF) was reported in a second positive sample within this
50 time period (cycle threshold N gene <27.8), assuming a reinfection with Omicron BA.1 briefly after
51 Delta infection.

52 Similarly, between January 1, 2022 and March 10, 2022 (n = 9 weeks), a period characterized by viral
53 replacement of Omicron BA.1 by BA.2, a total of 48,829 patients tested SARS-CoV-2 positive. Among
54 these, 0.01% (5 out of 48,829) presented an SGTF in a first sample but had an S-gene detected in a
55 second positive sample. Considering the epidemiological context during the latter period in this
56 region, reinfections with Omicron BA.2 after BA.1 infection were suspected in these patients.

57 In Figure 1, we report the age and vaccination status of these 96 patients with documented early
58 reinfection, compared to the vaccination rate for the same age groups in the same geographic region
59 (Flanders, Belgium) (8). Early reinfections were most frequently observed among young unvaccinated
60 patients (<12 years old). In all age groups, patients with early reinfection had a lower vaccination rate
61 compared to the corresponding age groups in the general population. Boosted patients had the
62 lowest risk of early SARS-CoV-2 reinfection. Median time between the last vaccine dose and
63 reinfection in all patients was 172 days (IQR 76-195 days). Median time between the two positive
64 samples with different VOC was 47 days (range 17-65 days).

65 Previous large retrospective cohort studies showing a prolonged maintenance of protection against
66 reinfection should be questioned in the context of Omicron (3). Our data confirms that early Omicron

67 BA.1 reinfection (<60 days) after Delta infection and BA.2 reinfection after a BA.1 infection can occur,
68 especially in young, unvaccinated individuals. In older patient groups, unvaccinated and patients with
69 a basic vaccination scheme are more vulnerable to reinfections compared to patients who received a
70 first booster vaccine. Data from Denmark (9) suggests reinfection usually results in mild disease not
71 requiring hospitalization as is illustrated by this reported case.


72 For this reason, we consider that the duration of protection offered by a previous infection should be
73 reconsidered, in particular when a shift between consecutive SARS-CoV-2 variants occurs. Testing
74 policies should not assume that patients do not need to be retested within a period of 60 days, as
75 reinfections, especially in unvaccinated young patients, are not inconceivable within this timeframe.
76 It has been repeatedly observed that a full viral population replacement can occur in a matter of a
77 few weeks, and such phenomenon will continue to impact the duration and efficacy of immunity in
78 the future.

1 **Table 1. Results of SARS-CoV-2 screening and vaccination status in the patient and his family.** All samples were analyzed
 2 using reverse transcription polymerase chain reaction, whole genome sequencing was performed on SARS-CoV-2 positive
 3 samples in the Belgian National Reference Center for Respiratory Pathogens (10).

		PATIENT	SIBLING	PARENT	PARENT
		Non-vaccinated	08/2021 BNT162b2 09/2021 BNT162b2	06/2021 BNT162b2 07/2021 BNT162b2	02/2021 ChAdOx1 05/2021 ChAdOx1 11/2021 BNT162b2
FIRST INFECTION	DECEMBER 2021				
	early	SARS-CoV-2 very strong positive ≥7.0 log copies/mL Delta (AY.43)	SARS-CoV-2 very strong positive ≥7.0 log copies/mL Delta (AY.43)	SARS-CoV-2 strong positive ≥5 - <7.0 log copies/mL Delta (AY.43)	SARS-CoV-2 negative
	early				SARS-CoV-2 negative
	mid	SARS-CoV-2 weak positive <3.0 log copies/mL untypable			
SECOND INFECTION	JANUARY 2022				
	early	SARS-CoV-2 strong positive 5.05 log copies/mL Omicron (BA.1)			
	mid	SARS-CoV-2 negative	SARS-CoV-2 weak positive <3.0 log copies/mL untypable	SARS-CoV-2 negative	
	mid	SARS-CoV-2 negative			

4

Figure 1. Number of patients with documented SARS-CoV-2 reinfection including vaccination status compared with age corresponding vaccination coverage in the community (i.e. Flanders, Belgium)



References

1. Mullen JL, Tsueng G, Abdel Latif A, Alkuzweny M, Cano M, Haag E, et al. Outbreak.info [Internet]. 2020 [cited 2022 Feb 4]. Available from: outbreak.info
2. Van der Straten K, Guerra D, Van Gils MJ, Bontjer I, Caniels TG, Van Willigen HDG, et al. Mapping the antigenic diversification of SARS-CoV-2. medRxiv [Internet]. 2022; Available from: <https://www.medrxiv.org/content/10.1101/2022.01.03.21268582v1%0Ahttps://www.medrxiv.org/content/10.1101/2022.01.03.21268582v1.abstract>
3. Kim P, Gordon SM, Sheehan MM, Rothberg MB. Duration of Severe Acute Respiratory Syndrome Coronavirus 2 Natural Immunity and Protection Against the Delta Variant: A Retrospective Cohort Study. Clin Infect Dis [Internet]. 2021 Dec 3;(Xx Xx):1–6. Available from: <https://academic.oup.com/cid/advance-article/doi/10.1093/cid/ciab999/6448857>
4. Planas D, Saunders N, Maes P, Guivel-Benhassine F, Planchais C, Buchrieser J, et al. Considerable escape of SARS-CoV-2 Omicron to antibody neutralization. Nature [Internet]. 2022 Feb 24;602(7898):671–5. Available from: <https://www.nature.com/articles/s41586-021-04389-z>
5. Pulliam JRC, Schalkwyk C van, Govender N, Gottberg A von, Cohen C, Groome MJ, et al. Increased risk of SARS-CoV-2 reinfection associated with emergence of the Omicron variant in South Africa. medRxiv [Internet]. 2021; Available from: <https://www.medrxiv.org/content/10.1101/2021.11.11.21266068v2%0Ahttps://www.medrxiv.org/content/10.1101/2021.11.11.21266068v2.abstract>
6. Rahman S, Rahman MM, Miah M, Begum MN, Sarmin M, Mahfuz M, et al. COVID-19 reinfections among naturally infected and vaccinated individuals. Sci Rep [Internet]. 2022 Dec 26;12(1):1438. Available from: <https://www.nature.com/articles/s41598-022-05325-5>
7. European Centre for Disease Prevention and Control. Reinfection with SARS-CoV-2: implementation of a surveillance case definition within the EU/EEA [Internet]. Stockholm; 2021. Available from: <https://www.ecdc.europa.eu/en/publications-data/reinfection-sars-cov-2-implementation-surveillance-case-definition-within-eueea>
8. Vaesen J. Covid Vaccinatie België [Internet]. 2022 [cited 2022 Mar 21]. Available from: <https://covid-vaccinatie.be/nl>
9. Stegger M, Edslev SM, Sieber RN, Ingham AnC, Ng KL, Tang M-HE, et al. Occurrence and

significance of Omicron BA . 1 infection followed by Corresponding author. medRxiv
[Internet]. 2022; Available from: <https://doi.org/10.1101/2022.02.19.22271112>

10. Pirnay J-P, Selhorst P, Hong SL, Cochez C, Potter B, Maes P, et al. Variant Analysis of SARS-CoV-2 Genomes from Belgian Military Personnel Engaged in Overseas Missions and Operations. *Viruses* [Internet]. 2021 Jul 13;13(7):1359. Available from: <https://www.mdpi.com/1999-4915/13/7/1359>